About 30M Genomics
Data last updated:
30M Genomics is a company based in Eluru (India) founded in 2019 by Benet Bosco Dhas, Pavani Pavuluri, and Yaswanth Reddy. 30M Genomics has raised $131.67 thousand across 4 funding rounds from investors including AIC-CCMB, JioGenNext and Amey Mashelkar. 30M Genomics offers products and services including Home Tests, SmartPGx, KeyPCR, AmpReady, and MagEase Kits. 30M Genomics operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter Eluru, India
- Founders Benet Bosco Dhas, Pavani Pavuluri, Yaswanth Reddy
- SectorsHealthcare
- EmailLocked
- PhoneLocked
- Website 30mgenomics.com
- Social LinkedIn Facebook Instagram YouTube
- Legal Name 30M Genomics Private Limited
- Date of Incorporation 18 Jul, 2019
- Jurisdiction West Godavari, Andhra Pradesh, India
- Annual Revenue$33.12 K (USD)584.4as on Mar 31, 2022
- Net Profit-$4.57 K (USD)-45.96as on Mar 31, 2022
- EBITDA-$32.05 K (USD)-316.13as on Mar 31, 2022
- Total Equity Funding$131.67 K (USD)
in 4 rounds
- Latest Funding Round$58.17 K (USD), Seed
Jan 03, 2025
- InvestorsAIC-CCMB
& 5 more
Associated legal entities of 30M Genomics
30M Genomics operates through 30M Genomics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors |
|---|---|---|---|---|---|---|
| 30M Genomics Private Limited Primary CIN U85300AP2019PTC112451 | Active | 18 Jul 2019 | West Godavari, Andhra Pradesh | ₹0.2 Cr | – | 2 |
People of 30M Genomics
3 people are tracked at 30M Genomics (3 in leadership).
| Name | Role | Group |
|---|---|---|
| Co-Founder & CEO | Leadership | |
| Co-Founder | Leadership | |
| Co-Founder | Leadership |
Complete people profiles for 30M Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Board of directors of 30M Genomics Private Limited (30M Genomics)
30M Genomics Private Limited is the primary company behind 30M Genomics. The board of 30M Genomics Private Limited currently have 2 directors; the longest-serving is Benet Bosco Dhas, appointed in 2019. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Benet Bosco Dhas DIN 08514206 | Director | 18 Jul 2019 | 7 yrs 2 mo | 30M Genomics Private Limited |
| Sasikanta Naga Pavani Pavuluri DIN 08514207 | Director | 18 Jul 2019 | 7 yrs 2 mo | 30M Genomics Private Limited |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of 30M Genomics
30M Genomics offers a comprehensive portfolio of products and services, including Home Tests, SmartPGx, KeyPCR, AmpReady, and MagEase Kits.
Saliva-based tests for personalized medicine and disease risk.
AI-driven reports for accurate drug dosing recommendations.
PCR-based kits for genetic disease and infectious analysis.
Ready-to-use kits for rapid genomics applications.
Kits for efficient DNA extraction and analysis.
Apps and channels of 30M Genomics
its YouTube channel 30M Genomics has 79 subscribers and 3 videos.
Financials of 30M Genomics
Figures of 30M Genomics Private Limited, the primary company behind 30M Genomics, for FY 2024. Revenue was ₹0.18 Cr (-38% year on year). Net loss was -₹0.22 Cr (-122% margin). EBITDA was -₹0.15 Cr (-87% margin). Revenue has grown at a compounded annual rate of +64% over three years.
- ₹0.18 CrRevenue · FY 2024 · -38% YoY
- -₹0.22 CrNet loss · -122% margin
- -₹0.15 CrEBITDA · -87% margin
- ₹0.01 CrPaid-up capital
- +64%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of 30M Genomics Private Limited are on its company page.
Detailed financial statements for 30M Genomics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Funding Insights of 30M Genomics
30M Genomics has successfully raised a total of $131.67K across 4 strategic funding rounds. The most recent funding activity was a Seed round of $58.17 thousand completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $131,674
- Total Rounds 4
- Last Round Seed — $58,172
- Investors Count 6
All 4 funding rounds of 30M Genomics with amounts, post-money valuations and investors.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| 03 Jan 2025 | $58,172 | Seed | – | Venture Center | – |
| 01 Nov 2021 | $73,502 | Seed | $748,088 | AIC-CCMB | |
| 08 Apr 2021 | Undisclosed | Grant | – | – | |
| 28 Jan 2021 | Undisclosed | Grant | – | – |
Last known valuation $748,088 (Nov 2021). 6 investors in total: 4 institutional and 2 angel.
Investors in 30M Genomics
30M Genomics has secured backing from 6 investors, including angel and venture fund investors. Prominent investors backing the company include AIC-CCMB, JioGenNext and Amey Mashelkar.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sector agnostic startup incubator | 2017 | aic.ccmb.res.in | Hyderabad, India | |
Startup engagement platform providing market access and guidance within the Reliance ecosystem. | 2013 | jiogennext.com | Mumbai, India | |
Startups are incubated at Venture Center, backed by CSIR. | – | venturecenter.co.in | Pune, India | |
AM Amey Mashelkar | - | – | unknown_67446619fd6948d39 | - |
RM Ra Mashelkar | - | – | unknown_c9491cf970014c7da | - |
A pan-industry alliance is formed to promote deeptech startups in India. | – | indiadeeptech.com | India |
Investor details for 30M Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of 30M Genomics
3 dated milestones of 30M Genomics across 6 years, from founding to its latest funding, stage changes and deals.
- 30M Genomics is founded.
- First funding round.
- Latest funding round, Seed, of $58K.
Competitors of 30M Genomics
30M Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347.0M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.8M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.2M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.7M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | |
| unitybiotechnology.com | 2016 | San Francisco, United States | $206.0M | – | Therapeutics for aging diseases are developed by targeting senescent cells. | |
| unilabs.com | 2000 | Geneva, Switzerland | – | – | Diagnostic services are provided through laboratories and radiology units. | |
| celsiustx.com | 2018 | Cambridge, United States | $148.0M | 50 | Single-cell RNA and genomic analysis for precision therapeutics are provided. | |
| intelliatx.com | 2014 | Cambridge, United States | $85.0M | 526 | Therapeutics using CRISPR/Cas9 are developed for various diseases. | |
| voyagertherapeutics.com | 2014 | Cambridge, United States | $105.0M | 183 | Gene Therapy to treat CNS diseases such as Parkinson’s disease, ALS. |
Detailed competitors of 30M Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Frequently Asked Questions about 30M Genomics
30M Genomics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
30M Genomics is headquartered in Eluru, India. It is registered at Eluru, Andhra Pradesh, India.
Benet Bosco Dhas is the current CEO of 30M Genomics. They have also founded this company.
30M Genomics is a funded company, having raised a total of $131.67K across 4 funding rounds to date.
Annual revenue of 30M Genomics is $33.12K as on Mar 31, 2022.
30M Genomics was established in 2019 in Eluru, India, within the biotechnology sector focused on precision medicine. Platforms such as PGx War have been created to personalize coumarin anticoagulant dosages for cardiovascular patients. EmerSep, a bedside tool for sepsis diagnostics, has also been developed to support clinical decision-making. Operations center on genomic applications for drug personalization and rapid diagnostics in healthcare settings.
30M Genomics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
30M Genomics offers Home Tests, SmartPGx, KeyPCR, AmpReady, and MagEase Kits.
30M Genomics has 6 investors. Key investors include AIC-CCMB, JioGenNext, Amey Mashelkar, Ra Mashelkar, and India DeepTech.
The valuation of 30M Genomics is $748.09K as of Nov 2021.
30M Genomics operates through 30M Genomics Private Limited.
The legal entities of 30M Genomics currently have 2 directors, including Benet Bosco Dhas, Sasikanta Naga Pavani Pavuluri.